secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Hawk Acquisition Corp (BKHA)
CIK:        0002000775
Form:       8-K
Filed at:   2026-10-13T20:16:09+00:00
Accession:  0001829126-26-011077
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

Black Hawk shareholders approve Vesicor Therapeutics merger; 2.09M shares redeemed at $12.04
--------------------------------------------------------------------------------

- All eight proposals passed at the October 13, 2026 extraordinary general meeting, including the Business Combination Agreement dated April 26, 2025 with Vesicor Therapeutics, Inc.
- Business Combination vote: 3,191,351 for, 20,165 against, 0 abstentions; about 77.3% of 4,153,577 outstanding shares present, constituting a quorum.
- Five post-closing directors elected: Luo Feng, Warren Hosseinion, Frederick Woodruff Field, Oded Levy and Qi Ouyang.
- 2,089,162 ordinary shares redeemed for $25,153,510.48 total, a per-share price of about $12.04; the Company is not permitting reversals of redemption elections.
- Other approvals: Cayman-to-Delaware domestication, new charter/bylaws, Nasdaq share issuance, Vesicor 2026 Equity Incentive Plan, and removal of the $5,000,001 net tangible asset condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2000775/000182912626011077/0001829126-26-011077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2000775/000182912626011077/blackhawkacq_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-011077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer